Share Twitter LinkedIn Facebook Email David I. Quinn, MD, shares his thoughts on the most interesting renal cell carcinoma (RCC) data being presented at the 2018 Annual Meeting Annual Meeting.
Tivozanib for RCC: Unpacking Efficacy, Safety, and Dose Optimization – Bradley McGregor, MD – Dana Farber Genitourinary 3 Mins Read
Renal Cell Carcinoma TiNivo-2 Study: Patient-Reported Outcomes in Treatment Post-ICI Kidney 3 Mins Read
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read